State Street Corp Purchases 560,242 Shares of Savara Inc (NASDAQ:SVRA)

State Street Corp lifted its position in Savara Inc (NASDAQ:SVRA) by 15.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,138,276 shares of the company’s stock after purchasing an additional 560,242 shares during the quarter. State Street Corp’s holdings in Savara were worth $17,546,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Choreo LLC bought a new position in shares of Savara during the 2nd quarter valued at about $59,000. DRW Securities LLC bought a new stake in Savara in the 2nd quarter worth approximately $62,000. Principal Financial Group Inc. boosted its stake in Savara by 64.4% in the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock worth $72,000 after buying an additional 6,973 shares in the last quarter. Profund Advisors LLC bought a new position in Savara during the second quarter valued at approximately $105,000. Finally, BNP Paribas Financial Markets raised its stake in shares of Savara by 258.9% during the third quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company’s stock worth $109,000 after acquiring an additional 18,534 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Stock Down 1.5 %

Savara stock opened at $3.20 on Wednesday. Savara Inc has a one year low of $2.82 and a one year high of $5.70. The stock has a fifty day moving average of $3.46 and a 200 day moving average of $3.98. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. The stock has a market cap of $549.18 million, a PE ratio of -7.44 and a beta of 0.92.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.11). As a group, sell-side analysts predict that Savara Inc will post -0.45 EPS for the current year.

Insider Buying and Selling

In other Savara news, Director Joseph S. Mccracken acquired 20,000 shares of the stock in a transaction on Tuesday, November 19th. The stock was acquired at an average price of $2.95 per share, for a total transaction of $59,000.00. Following the completion of the transaction, the director now directly owns 210,837 shares of the company’s stock, valued at $621,969.15. This trade represents a 10.48 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Matthew Pauls sold 54,702 shares of the business’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $3.31, for a total transaction of $181,063.62. Following the completion of the sale, the chief executive officer now owns 1,536,379 shares in the company, valued at approximately $5,085,414.49. This trade represents a 3.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.13% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Wells Fargo & Company assumed coverage on shares of Savara in a research report on Friday, December 20th. They set an “overweight” rating and a $8.00 price target for the company. JMP Securities restated a “market outperform” rating and set a $9.00 target price on shares of Savara in a report on Thursday, December 19th. Evercore ISI reaffirmed an “in-line” rating and issued a $5.00 price target (down from $7.00) on shares of Savara in a research note on Wednesday, November 13th. Finally, HC Wainwright lowered their price objective on Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $9.86.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.